Deferasirox: Uncertain future following renal failure fatalities, agranulocytosis and other toxicities

Expert Opinion on Drug Safety

Volumn 6, Issue 3, 2007, Pages 235-239

  Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Agranulocytosis; Chelation therapy; Deferasirox; Deferiprone; Deferoxamine; Faralities; Renal failure; Thalassaemia; Toxicity; Transfusional iron overload

Indexed keywords

1 HYDROXY 4 METHOXYPYRID 2 ONE; 8 QUINOLINOL; ANTACID AGENT; CHELATING AGENT; CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; MALTOL; ORPHAN DRUG; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BLOOD TRANSFUSION; CATARACT; CHELATION THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EDITORIAL; EUROPEAN UNION; EYE DISEASE; EYE EXAMINATION; FERRITIN BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; HEARING; HEARING DISORDER; HEARING LOSS; HEARING TEST; HUMAN; INFECTION; INTRAOCULAR PRESSURE; IRON OVERLOAD; IRON STORAGE; KIDNEY INJURY; LIVER FUNCTION TEST; LIVER TOXICITY; MYELODYSPLASIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PATIENT COMPLIANCE; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; RETINA DISEASE; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN DISEASE; STOMACH DISEASE; STRUCTURE ACTIVITY RELATION; THALASSEMIA; THROMBOCYTOPENIA; TOXIC HEPATITIS; VOMITING; CHEMICALLY INDUCED DISORDER; METABOLISM;

AGRANULOCYTOSIS; BENZOIC ACIDS; CHELATING AGENTS; HUMANS; IRON; KIDNEY FAILURE, ACUTE; PRODUCT SURVEILLANCE, POSTMARKETING; TRIAZOLES;

EID: 34248567047     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.3.235     Document Type: Editorial

References (26)

1. WORLD HEALTH ORGANISATION: Community control of hereditary anaemias WHO Bull. (1983) 61:63-80.
2. KONTOGHIORGHES GJ, ERACLEOUS E, ECONOMIDES CH, KOLNAGOU A: Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL-670, GT-56-252, L1NAI1 and their combinations. Curr. Med. Chem. (2005) 12:2663-2681.
3. KONTOGHIORGHES GJ, NEOCLEOUS K, KOLNAGOU A: Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. (2003) 26:553-584.
4. ZURLO MG, DE STEFANO P, BORGNA-PIGNATTI C et al.: Survival and causes of death in thalassaemia major. Lancet (1989) 2(8653):27-30.
5. NICK H, ACKLIN P, LATTMANN R et al.: Development of tridentate iron chelators: from desferriothiocin to ICL-670. Curr. Med. Chem. (2003) 10:1065-1076.
6. NISBET-BROWN E, OLIVIERI NF, GIARDINA PJ et al.: Effectiveness and safety of ICL-670 in iron-loaded patients with thalassaemia: a randomised double blind, placebo-contolled, dose escalation trial. Lancet (2003) 361:1597-1602.
7. GALANELLO R, PIGA A, ALBERTI D, ROUAN MC, BIGLER H, SECHAUD R: Safety, tolerability and pharmacokinetics of ICL-670, a new orally active iron chelating agent in patients with transfusion-dependent iron overload due to β-thalassaemia. J. Clin. Pharmacol. (2003) 43:565-572.
8. CAPPELINI MD: Iron-chelating therapy with the new oral agent ICL-670 (Exjade). Best Prac. Res. Clin. Haematol. (2005) 18:289-298.
9. PORTER J: Deferasirox: an effective once-daily orally active iron chelator. Drugs Today (Barc). (2006) 42:623-637.
10. VICHINSKY E, ONYEKWERE O, PORTER J et al.; DEFERASIROX IN SICKLE CELL INVESTIGATORS: A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br. J. Haematol. (2007) 136:501-508.
11. Exjade (deferasirox) tablets for oral suspension. Prescribing information. Novartis Pharmaceutical Corp. USA (NDA 21-882). October (2006):1-12.
12. Exjade (deferasirox) tablets for oral suspension update. Keeping you informed about changes to the Exjade prescribing information. Novartis Oncology, USA (EXJ-OT-0623-A). November (2006):1.
13. CRATPER MCLACHLAN DR, DALTON AJ, KRUCH TPA et al.: Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet (1991) 337(8753):1304-1308.
14. YAMAMOTO RS, WILLIAMS GM, FRANGEL HH, WEISBURGER JH: 8-Hydroxyquinoline: chronic toxicity and inhibitory effect on the carcinogenicity of N-2-fluorenylacetamide. Toxicol. Appl. Pharmacol. (1971) 19:687-698.
15. WOOD JC, OTT0-DUESSEL M, CONZALEZ I et al.: Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl. Res. (2006) 148:272-280.
16. KONTOGHIORGHES GJ: Do we need more iron chelating drugs? Lancet (2003) 362:495-496.
17. KOLNAGOU A, KONTOGHIORGHES GJ: Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the international committee on oral chelators. Hemoglobin (2006) 30:239-249.
18. MODELL B, KHAN M, DARLISON M: Survival in beta-thalassaemia major in the UK: data from the UK register. Lancet (2000) 355:2051-2052.
19. TEFLER P, GOEN PG, CHRISTOU S et al.: Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980 - 2004. Haematologica (2006) 91:1187-1192.
20. PENNEL DJ, BERDOUKAS V, KARAGIORGA M et al.: Randomised controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2006) 107:3738-3744.
21. HENTER JI, KARLEN J: Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood (2007) (In Press).
22. SHASHATY G, FRANKEWICH R, CHAKRABORTI T et al.: Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park) (2006) 20:1799-1806
23. KONTOGHIORGHES GJ: Chelators affecting iron absorption in mice. Arzneimittel-Forschung/Drug Research (1990) 40:1332-1335.
24. ANDERSON LJ, WESTWOOD MA, HOLDEN S et al.: Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br. J. Haematol. (2004) 127:348-355.
25. KONTOGHIORGHES GJ: Effects of ICL-670 (deferasirox) on cardiac iron concentration. Lancet (2005) 366:804.
26. KONTOGHIORGHES GJ: New oral iron-chelating drugs for the treatment of transfusional iron overlosd and other diseases. Drugs Future (2006) 30:1241-1251.